tradingkey.logo
搜尋

Pluri Inc

PLUR
添加自選
2.110USD
-0.030-1.44%
收盤 07/02, 13:00美東報價延遲15分鐘
22.01M總市值
虧損本益比TTM

Pluri Inc

2.110
-0.030-1.44%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.44%

5天

+3.87%

1月

-11.34%

6月

-29.43%

今年開始到現在

-29.43%

1年

-63.50%

關鍵數據
2.110今開
2.140最高
2.22K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.02%換手率
2.090昨收
2.110最低
3.23K成交額
虧損本益比靜
-1.18市淨率
0.00%股息率 TTM
-84.91%ROA
5.96052週最高
0.55量比
-22.58M淨利潤
10.43M總股本
-2.9077每股盈餘TTM
0.66Beta
-1205.58%ROE
2.22052週最低
1.44%振幅
33.53%毛利率
22.01M總市值
-3.19回報/風險
3.82%風險率

TradingKey Pluri Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Pluri Inc當前公司基本面數據相對謹慎,增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名242/387位。機構持股佔比非常高,近一月多位分析師給出公司評級為。最高目標價為12.00。中期看,股價處於下降通道。近一個月,市場表現較差,基本面和技術面綜合得分也較低。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Pluri Inc評分

相關信息

行業排名
242 / 387
全市場排名
506 / 4565
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

Pluri Inc亮點

亮點風險
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
業績高增長
公司營業收入穩步增長,連續3年增長365.51%
業績增長期
公司處於發展階段,最新年度總收入1.34M美元
估值高估
公司最新PE估值-0.73,處於3年歷史高位
機構減倉
最新機構持股1.35M股,環比減少3.15%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股

分析師目標

基於 0 分析師
--
評級
12.000
目標均價
+397.93%
漲幅空間

Pluri Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Pluri Inc簡介

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
公司代碼PLUR
公司Pluri Inc
CEOYanay (Yaky)
網址https://pluri-biotech.com/

常見問題

Pluri Inc(PLUR)的當前股價是多少?

Pluri Inc(PLUR)的當前股價是 2.11。

Pluri Inc 的股票代碼是什麼?

Pluri Inc的股票代碼是PLUR。

Pluri Inc股票的52週最高點是多少?

Pluri Inc股票的52週最高點是5.96。

Pluri Inc股票的52週最低點是多少?

Pluri Inc股票的52週最低點是2.22。

Pluri Inc的市值是多少?

Pluri Inc的市值是22.01M。

Pluri Inc(PLUR)股票的每股收益(EPS TTM)是多少

Pluri Inc(PLUR)股票的每股收益(EPS TTM)是-3.56。